Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 5/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17311919 | 1.00 | SUV39H2 (0.38) | SUV39H2CTSKJAK3BTKGAA | |
| SCHEMBL1712785 | 0.89 | GAA (0.36) | SUV39H2CTSKJAK3BTKGAA | |
| SCHEMBL2290718 | 0.86 | GAA (0.36) | SUV39H2CTSKJAK3BTKGAA | |
| SCHEMBL1723447 | 0.84 | GAA (0.39) | CTSKGAANFKB1NFKB2RELA | |
| SCHEMBL1723595 | 0.84 | GAA (0.38) | SUV39H2CTSKJAK3GAANFKB1 | |
| SCHEMBL1722713 | 0.84 | GAA (0.38) | GAANFKB1NFKB2RELAKDM4D | |
| SCHEMBL2286542 | 0.84 | NFKB1 (0.40) | SUV39H2JAK3BTKGAANFKB1 | |
| SCHEMBL2287071 | 0.83 | GAA (0.38) | GAANFKB1NFKB2RELADRD2 | |
| SCHEMBL1723562 | 0.78 | GAA (0.39) | JAK3GAANFKB1NFKB2RELA | |
| SCHEMBL1723261 | 0.78 | GAA (0.39) | JAK3GAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2344495-B1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344495-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | SUV39H2 1770/4885CTSK 3780/4885JAK3 2271/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | SUV39H2 1575/4885CTSK 3594/4885JAK3 2023/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | SUV39H2 1755/4885CTSK 3379/4885JAK3 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.